Targeted protein degradation (TPD) via the proteasomal and lysosomal pathways is a promising therapeutic approach that represents a novel tool for exploring cellular pathways. TPD offers several key advantages over traditional occupancy-based inhibitors, notably concerning dosing, drug resistance, and side effects.